Figure 1.
Dermatomes of measurement for quantitative sensory testing.
Quantitative sensory testing was performed on the following sites on the dominant body side (black dots): clavicle (C5 dermatome), sternum (T4 dermatome), pancreatic site (dorsal and ventral T10 dermatome), hip region (L1 dermatome) and knee (L4 dermatome).
Figure 2.
Study enrollment and randomization.
The majority of patients not meeting inclusion criteria had passed away, were free of pain or were no longer being treated in either of the hospitals.
Table 1.
Demographic and clinical characteristics of patients.
Table 2.
Baseline data for conditioned pain modulation and sum of pain thresholds for pancreatitis patients vs. healthy controls.
Table 3.
Sum of pain thresholds for pregabalin vs. placebo before and after treatment.
Table 4.
Conditioned pain modulation and pain thresholds for pregabalin vs. placebo before and after study treatment.
Table 5.
Change and percentage change in conditioned pain modulation and pain thresholds for pregabalin vs. placebo after study treatment.